Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

Novavax raised its full-year adjusted revenue forecast on Wednesday, betting on the strength of vaccine supply partnerships, including with Serum Institute of India and Japan's Takeda , sending its ...

Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax ( ($NVAX) ) has risen by 24.00%. Read on to learn why. Novavax has experienced a notable 24.00% increase in its stock price over the past ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

Novavax beats Q2 expectations with $239 million in revenue, lifts 2025 guidance, and reports profit as costs decline and ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

(Reuters) -Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone ...

Novavax (NVAX) stock gains as the company beats Q2 revenue estimates and raises its 2025 revenue outlook, buoyed by ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Novavax stock has plummeted from $290 a share in February 2021 to around $50 recently. The FDA finally appears poised to authorize the company's vaccine, however.